These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 14518715)

  • 1. Genetic heterogeneity of hepatitis C virus (HCV) in clinical strains of HIV positive and HIV negative patients chronically infected with HCV genotype 3a.
    Bagaglio S; Bruno R; Lodrini S; De Mitri MS; Andreone P; Loggi E; Galli L; Lazzarin A; Morsica G
    J Biol Regul Homeost Agents; 2003; 17(2):153-61. PubMed ID: 14518715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response.
    Sarrazin C; Kornetzky I; Rüster B; Lee JH; Kronenberger B; Bruch K; Roth WK; Zeuzem S
    Hepatology; 2000 Jun; 31(6):1360-70. PubMed ID: 10827164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quasispecies of hepatitis C virus genotype 1 and treatment outcome with peginterferon and ribavirin.
    Jardim AC; Yamasaki LH; de Queiróz AT; Bittar C; Pinho JR; Carareto CM; Rahal P; Mello IM
    Infect Genet Evol; 2009 Jul; 9(4):689-98. PubMed ID: 19063998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in the NS5A gene are associated with response to interferon+ribavirin combination therapy in patients with chronic hepatitis C virus 3a infection.
    Ullah S; Rehman HU; Idrees M
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1146-51. PubMed ID: 23611896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin.
    Hung CH; Lee CM; Lu SN; Lee JF; Wang JH; Tung HD; Chen TM; Hu TH; Chen WJ; Changchien CS
    J Viral Hepat; 2003 Mar; 10(2):87-94. PubMed ID: 12614464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.
    Bolcic F; Laufer N; Torres C; Cassino L; Reynoso R; Quarleri J
    Antiviral Res; 2012 Aug; 95(2):72-81. PubMed ID: 22683884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HCV RNA decline in the first 24 h exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin.
    Laufer N; Bolcic F; Rolón MJ; Martinez A; Reynoso R; Pérez H; Salomón H; Cahn P; Quarleri J
    Antiviral Res; 2011 Apr; 90(1):92-7. PubMed ID: 21376083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches.
    Ballesteros AL; Franco S; Fuster D; Planas R; Martínez MA; Acosta L; Sirera G; Salas A; Tor J; Rey-Joly C; Clotet B; Tural C
    AIDS; 2004 Jan; 18(1):59-66. PubMed ID: 15090830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in the NS5A region do not predict interferon-responsiveness in american patients infected with genotype 1b hepatitis C virus.
    Chung RT; Monto A; Dienstag JL; Kaplan LM
    J Med Virol; 1999 Aug; 58(4):353-8. PubMed ID: 10421401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy*.
    Yuan HJ; Jain M; Snow KK; Gale M; Lee WM;
    J Viral Hepat; 2010 Mar; 17(3):208-16. PubMed ID: 19656286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa.
    Zeuzem S; Lee JH; Roth WK
    Hepatology; 1997 Mar; 25(3):740-4. PubMed ID: 9049228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.
    Muñoz de Rueda P; Casado J; Patón R; Quintero D; Palacios A; Gila A; Quiles R; León J; Ruiz-Extremera A; Salmerón J
    J Virol; 2008 Jul; 82(13):6644-53. PubMed ID: 18448540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations.
    Pawlotsky JM; Germanidis G; Neumann AU; Pellerin M; Frainais PO; Dhumeaux D
    J Virol; 1998 Apr; 72(4):2795-805. PubMed ID: 9525599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
    Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
    Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C.
    Puig-Basagoiti F; Sáiz JC; Forns X; Ampurdanès S; Giménez-Barcons M; Franco S; Sánchez-Fueyo A; Costa J; Sánchez-Tapias JM; Rodés J
    J Med Virol; 2001 Sep; 65(1):35-44. PubMed ID: 11505441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus.
    Sáiz JC; López-Labrador FX; Ampurdanés S; Dopazo J; Forns X; Sánchez-Tapias JM; Rodés J
    J Infect Dis; 1998 Apr; 177(4):839-47. PubMed ID: 9534954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirin.
    Dal Pero F; Tang KH; Gerotto M; Bortoletto G; Paulon E; Herrmann E; Zeuzem S; Alberti A; Naoumov NV
    J Infect Dis; 2007 Oct; 196(7):998-1005. PubMed ID: 17763320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy.
    Sarrazin C; Bruckner M; Herrmann E; Rüster B; Bruch K; Roth WK; Zeuzem S
    Virology; 2001 Oct; 289(1):150-63. PubMed ID: 11601926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNα-2a/RBV combination therapy in Azerbaijani patients.
    Bokharaei-Salim F; Keyvani H; Salehi-Vaziri M; Sadeghi F; Monavari SH; Mehrnoush L; Alavian SM
    Arch Virol; 2014 Nov; 159(11):2893-9. PubMed ID: 25139545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hepatitis C virus NS5A protein and response to interferon alpha: mutational analyses in patients with chronic HCV genotype 3a infection from India.
    Goyal A; Hofmann WP; Hermann E; Traver S; Hissar SS; Arora N; Blum HE; Zeuzem S; Sarrazin C; Sarin SK
    Med Microbiol Immunol; 2007 Mar; 196(1):11-21. PubMed ID: 16955308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.